2. Index 2008Index 2010 # Companies Originators 1820 # Companies Generic Manufacturers 2 Same Index, adjusted weights 7 Separate Index, adjus weights / KPIs Diseases Scope *Includes Communicable & Non- Communicable Diseases 26 Mortality-based 33 Morbidity-based Inc: NCD’s Country Scope 88 UN HDI 2006. Exclusions for WB’s ‘medium-high’ & ‘high’ Number of KPIs 28106 (111) Weight Adjustments Adjustments for single disease area co’s. Based on Originator / Generic revenue streams Products covered Predominantly MedicinesVaccines, diagnostics, new technologies & paediatrics Access to Medicine Index Methodology Changes Between Index 2008 & Index 2010

3. Index 2008 Public Policy & Advocacy R&D Patents & Licensing Capacity Equitable Pricing Donations Philanthropy ATM Management 3 Access to Medicine Index Methodology Structural Changes for Index 2010

4. Access to Medicine Index Methodology Evolves in-line with Global Health Environment Index 2008 Index 2010 2012 Stakeholder Review & Methodology Update Process Significant Changes Incremental Changes  To adjust methods to changing global healthcare priorities  To improve methodology based on learning from past indices

6. Data Collection Process Where Does Our Data Come From? Company Originated Company Annual Report / SEC filings Company CSR / Sustainability Docs Company Websites / pages Qualitative Questionnaire Excel: R&D Pipeline Excel: Product Portfolio Company Originated Company Annual Report / SEC filings Company CSR / Sustainability Docs Company Websites / pages Qualitative Questionnaire Excel: R&D Pipeline Excel: Product Portfolio Third-Party Sources Databases: Factiva/Lexis Nexus Mulitlateral / G’ment Reports Civil Society / NGO Reports Academic Literature Interviews with Partners (iNGO’s, PDPs, patent pool, donation orgs etc) Media Databases (Index Country media) Third-Party Sources Databases: Factiva/Lexis Nexus Mulitlateral / G’ment Reports Civil Society / NGO Reports Academic Literature Interviews with Partners (iNGO’s, PDPs, patent pool, donation orgs etc) Media Databases (Index Country media) Index Database

7. Strategic Pillars CommitmentsTransparencyPerformanceInnovation Technical Areas General Access to Medicine Management Public Policy and Market Influence Research & Development Equitable Pricing, Manufacturing & Distribution Patents & Licensing Capability Advancement Advancement in Product Development and Distribution Product Donations & Philanthropic Activities Index Structure: strategic drivers Commitments o Indicator of future performance o Robustness (detailed? with clear goals? Supported by operational targets?) o Policy Stances – publicly available? o Indicator of future performance o Robustness (detailed? with clear goals? Supported by operational targets?) o Policy Stances – publicly available?

8. Strategic Pillars CommitmentsTransparencyPerformanceInnovation Technical Areas General Access to Medicine Management Public Policy and Market Influence Research & Development Equitable Pricing, Manufacturing & Distribution Patents & Licensing Capability Advancement Advancement in Product Development and Distribution Product Donations & Philanthropic Activities Index Structure: strategic drivers Transparency o Improving accountability to stakeholders (focus on public disclosure and quality of disclosure) o Facilitate learning – focus on process disclosure o Improve internal company (and sector-wide) reporting o Improving accountability to stakeholders (focus on public disclosure and quality of disclosure) o Facilitate learning – focus on process disclosure o Improve internal company (and sector-wide) reporting

9. Strategic Pillars CommitmentsTransparencyPerformanceInnovation Technical Areas General Access to Medicine Management Public Policy and Market Influence Research & Development Equitable Pricing, Manufacturing & Distribution Patents & Licensing Capability Advancement Advancement in Product Development and Distribution Product Donations & Philanthropic Activities Index Structure: strategic drivers Performance o “Ideally”, capturing the impact of companies on health burden “on the ground”. o Remains to be the focus area of the Index for improvement & will gradually improve over time o “Ideally”, capturing the impact of companies on health burden “on the ground”. o Remains to be the focus area of the Index for improvement & will gradually improve over time

10. Strategic Pillars CommitmentsTransparencyPerformanceInnovation Technical Areas General Access to Medicine Management Public Policy and Market Influence Research & Development Equitable Pricing, Manufacturing & Distribution Patents & Licensing Capability Advancement Advancement in Product Development and Distribution Product Donations & Philanthropic Activities Index Structure: strategic drivers Business Model Innovation o Focus on business model Innovation (‘new approaches’) o Uniqueness o Promise of impact or realised impact o Key strategic pillar for learning o Focus on business model Innovation (‘new approaches’) o Uniqueness o Promise of impact or realised impact o Key strategic pillar for learning

11. Strategic Pillars CommitmentsTransparencyPerformanceInnovation Technical Areas General Access to Medicine Management Public Policy and Market Influence Research & Development Equitable Pricing, Manufacturing & Distribution Patents & Licensing Capability Advancement Advancement in Product Development and Distribution Product Donations & Philanthropic Activities Index Structure: Seven Technical Areas Each area has 2–3 sub-topics of focus For example: 1.Advocacy and Lobbying 2.Competition Behavior 3.Marketing Behavior For example: 1.Advocacy and Lobbying 2.Competition Behavior 3.Marketing Behavior For example: 1.Innovative R&D 2.Adaptive R&D 3.Intellectual Property Sharing For example: 1.Innovative R&D 2.Adaptive R&D 3.Intellectual Property Sharing

12. 12 Technical Areas A. General Access to Medicine Management ATM Governance ATM Management System Stakeholder Engagement B. Public Policy and Market Influence Advocacy and Lobbying Competition Behavior Marketing Behavior C. Research and Development Innovative R&D Adaptive R&D Intellectual Property Sharing D. Equitable Pricing, Manufacturing and Distribution Marketing Approval (Registration) Equitable Pricing Manufacturing & Distribution E. Patents & Licensing Patents Non-Exclusive Voluntary Licensing F. Capability Advancement in Product Development and Distribution Capacity Building in Research and Development Capacity Building in Quality Management and Distribution G. Product Donations and Philanthropic Activities Donations Philanthropy Access to Medicine Index Methodology Issue Focus of Technical Areas

13. 13 For the analysis of all companies we always focus on the depth and breadth of the companies ‘access’ initiatives: – All approved products targeting Index Diseases – not just the flagship programmes(portfolio analysis) – All areas of R&D activity for eligible areas (pipeline analysis) It is a relative index. Score of 5 indicates leading practice compared with peers, score of zero indicates lagging practice and 2.5 aims to reflect average practice. Data Analysis Process The bigger picture

14. 14